TY  - JOUR
T1  - ANdrogen deprivation therapy for prostate cancer and cardiovascular death—reply
AU  - Nguyen PL, Je Y, Choueiri TK
Y1  - 2012/03/28
N1  - 10.1001/jama.2012.353
JO  - JAMA
SP  - 1252
EP  - 1253
VL  - 307
IS  - 12
N2  - 
In Reply: The physiological effects of ADT typically persist long after cessation of treatment, particularly in men older than 70 years who comprised the majority of patients in the trials included in our meta-analysis. Testosterone suppression often persists for 2 or more years after ADT is stopped.1- 3 Thus, the interval between ADT-induced testosterone suppression and data collection is actually shorter than it may appear. However, our study cannot rule out the possibility that fatal cardiac events could be occurring earlier in men exposed to ADT.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.353
UR  - http://dx.doi.org/10.1001/jama.2012.353
ER  -